Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab

被引:0
作者
T D Papakostas
L Lim
T van Zyl
J B Miller
B S Modjtahedi
C M Andreoli
D Wu
L H Young
I K Kim
D G Vavvas
D D Esmaili
D Husain
D Eliott
L A Kim
机构
[1] Retina Service,
[2] Massachusetts Eye and Ear Infirmary,undefined
[3] Harvard Medical School,undefined
[4] Harvard Vanguard Medical Associates,undefined
[5] Retina-Vitreous Associates Medical Group,undefined
来源
Eye | 2016年 / 30卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:79 / 84
页数:5
相关论文
共 111 条
[1]  
Ip MS(2009)A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care Arch Ophthalmol 127 1101-2460
[2]  
Scott IU(2011) Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5 Ophthalmology 118 2453-1133.e1
[3]  
VanVeldhuisen PC(2010)Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results Ophthalmology 117 1124-456
[4]  
Oden NL(2009)Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Br J Ophthalmol 93 452-621
[5]  
Blodi BA(2011)Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial J Ocul Pharmacol Ther 27 615-2049
[6]  
Fisher M(2011)Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial Ophthalmology 118 2041-1063
[7]  
Haller JA(2013)Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 120 1057-185
[8]  
Bandello F(2012)Predictive value in retinal vein occlusions of early Angiogenesis 15 171-208
[9]  
Belfort R(2014) late or incomplete ranibizumab response defined by optical coherence tomography Ophthalmology 121 202-1420.e1
[10]  
Blumenkranz MS(2014)Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Ophthalmology 121 1414-2443